secwatch.observer — SEC 8-K summary
======================================

Issuer:     PMV Pharmaceuticals, Inc. (PMVP)
CIK:        0001699382
Form:       8-K
Filed at:   2023-03-01T23:59:59+00:00
Accession:  0000950170-23-005343
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PMV Pharma reports FY2022 net loss $73.3M; cash $243.5M; PC14586 update expected 2H 2023
--------------------------------------------------------------------------------

- Net loss $73.3M in FY2022 vs $57.8M in FY2021; R&D expenses rose to $52.0M from $36.5M.
- Cash, equivalents, and marketable securities $243.5M at Dec 31, 2022, down from $314.1M.
- Phase 1/2 PYNNACLE study of PC14586 ongoing; first patient enrolled in combination arm with KEYTRUDA.
- WIP-1 and R273H programs put on hold; projected cash runway extended to 1H 2025.
- Appointed Kirsten Flowers and Carol Gallagher to Board; promoted Michael Carulli to SVP Finance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1699382/000095017023005343/0000950170-23-005343-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1699382/000095017023005343/pmvp-20230301.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-005343

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer